Pharmacology complex compound of pro-gly-pro-leu with heparin: hypoglycemic, fibrinolitic and anticoagulant effects in rats with hyperglycemia
Previously it was shown that the use of regulatory peptides of the glyprolin family helps to normalize the hemostasis system and blood glucose levels in experimental resistant hyperglycemia in rats, similar to type 2 diabetes mellitus in humans. It is also known that the anticoagulant heparin inhibi...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Volgograd State Medical University, Pyatigorsk Medical and Pharmaceutical Institute
2019-12-01
|
| Series: | Фармация и фармакология (Пятигорск) |
| Subjects: | |
| Online Access: | https://www.pharmpharm.ru/jour/article/view/516 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849339522852061184 |
|---|---|
| author | T. Yu. Obergan N. F. Myasoedov M. E. Grigorjeva L. A. Lyapina T. A. Shubina L. A. Andreeva |
| author_facet | T. Yu. Obergan N. F. Myasoedov M. E. Grigorjeva L. A. Lyapina T. A. Shubina L. A. Andreeva |
| author_sort | T. Yu. Obergan |
| collection | DOAJ |
| description | Previously it was shown that the use of regulatory peptides of the glyprolin family helps to normalize the hemostasis system and blood glucose levels in experimental resistant hyperglycemia in rats, similar to type 2 diabetes mellitus in humans. It is also known that the anticoagulant heparin inhibits blood coagulation and exhibits a hypoglycemic effect in the body.The aim of the study is to obtain a complex of the Pro-Gly-Pro-Leu (PGPL) peptide and the unfractionated heparin, to study its effect on glucose and anticoagulant fibrinolytic properties and show its ability to restore the impaired functions of the insular and coagulating blood systems in experimental hyperglycemia in rats.Materials and Methods. Laboratory Wistar male rats, intact and with experimentally induced hyperglycemia, were used in the experiment. A complex compound of PGPL and heparin was created with a component ratio of 1:1 (mol/mol), which was administered intranasally to hyperglycemic rats once a day for 5 days at the dose of 1 mg/kg. Similarly, the constituent parts of the complex were administrated in equivalent amounts. The anticoagulant activity was determined by the test of activated partial thromboplastin time, fibrinolysis parameters - by tests of total, enzymatic and non-enzymatic fibrinolytic activities, as well as the activity of a tissue plasminogen activator. In addition, blood glucose was measured using special test strips. Results. The use of the PGPL-heparin complex in the animals with hyperglycemia led to normalization of blood glucose levels, an increase in the anticoagulant and fibrinolytic background of blood plasma. These effects persisted for 6 days after the cancellation of the peptide-heparin complex administration to rat.Conclusion. In the development of experimental hyperglycemia, the PGPL complex with heparin exhibits a combined hypo-glycemic, anticoagulant and fibrinolytic enzymatic and non-enzymatic nature of the effect. In the future, the studied peptide-heparin complex can be used for the prevention and treatment of type 2 diabetes mellitus, complicated by increased blood coagulation. |
| format | Article |
| id | doaj-art-fa2c63c8b106428faf3b9489d302cf98 |
| institution | Kabale University |
| issn | 2307-9266 2413-2241 |
| language | Russian |
| publishDate | 2019-12-01 |
| publisher | Volgograd State Medical University, Pyatigorsk Medical and Pharmaceutical Institute |
| record_format | Article |
| series | Фармация и фармакология (Пятигорск) |
| spelling | doaj-art-fa2c63c8b106428faf3b9489d302cf982025-08-20T03:44:06ZrusVolgograd State Medical University, Pyatigorsk Medical and Pharmaceutical InstituteФармация и фармакология (Пятигорск)2307-92662413-22412019-12-017530030710.19163/2307-9266-2019-7-5-300-307321Pharmacology complex compound of pro-gly-pro-leu with heparin: hypoglycemic, fibrinolitic and anticoagulant effects in rats with hyperglycemiaT. Yu. Obergan0N. F. Myasoedov1M. E. Grigorjeva2L. A. Lyapina3T. A. Shubina4L. A. Andreeva5Lomonosov Moscow State University, Faculty of Biology, Laboratory of protective blood systems n. a. prof. B.A. KudryashovInstitute of Molecular Genetics, Russian Academy of SciencesLomonosov Moscow State University, Faculty of Biology, Laboratory of protective blood systems n. a. prof. B.A. KudryashovLomonosov Moscow State University, Faculty of Biology, Laboratory of protective blood systems n. a. prof. B.A. KudryashovLomonosov Moscow State University, Faculty of Biology, Laboratory of protective blood systems n. a. prof. B.A. KudryashovInstitute of Molecular Genetics, Russian Academy of SciencesPreviously it was shown that the use of regulatory peptides of the glyprolin family helps to normalize the hemostasis system and blood glucose levels in experimental resistant hyperglycemia in rats, similar to type 2 diabetes mellitus in humans. It is also known that the anticoagulant heparin inhibits blood coagulation and exhibits a hypoglycemic effect in the body.The aim of the study is to obtain a complex of the Pro-Gly-Pro-Leu (PGPL) peptide and the unfractionated heparin, to study its effect on glucose and anticoagulant fibrinolytic properties and show its ability to restore the impaired functions of the insular and coagulating blood systems in experimental hyperglycemia in rats.Materials and Methods. Laboratory Wistar male rats, intact and with experimentally induced hyperglycemia, were used in the experiment. A complex compound of PGPL and heparin was created with a component ratio of 1:1 (mol/mol), which was administered intranasally to hyperglycemic rats once a day for 5 days at the dose of 1 mg/kg. Similarly, the constituent parts of the complex were administrated in equivalent amounts. The anticoagulant activity was determined by the test of activated partial thromboplastin time, fibrinolysis parameters - by tests of total, enzymatic and non-enzymatic fibrinolytic activities, as well as the activity of a tissue plasminogen activator. In addition, blood glucose was measured using special test strips. Results. The use of the PGPL-heparin complex in the animals with hyperglycemia led to normalization of blood glucose levels, an increase in the anticoagulant and fibrinolytic background of blood plasma. These effects persisted for 6 days after the cancellation of the peptide-heparin complex administration to rat.Conclusion. In the development of experimental hyperglycemia, the PGPL complex with heparin exhibits a combined hypo-glycemic, anticoagulant and fibrinolytic enzymatic and non-enzymatic nature of the effect. In the future, the studied peptide-heparin complex can be used for the prevention and treatment of type 2 diabetes mellitus, complicated by increased blood coagulation.https://www.pharmpharm.ru/jour/article/view/516anticoagulant activityblood glucose levelcomplex compoundfibrinolysisglyprolin peptideshyperglycemiatype 2 diabetes mellitus (t2dm) |
| spellingShingle | T. Yu. Obergan N. F. Myasoedov M. E. Grigorjeva L. A. Lyapina T. A. Shubina L. A. Andreeva Pharmacology complex compound of pro-gly-pro-leu with heparin: hypoglycemic, fibrinolitic and anticoagulant effects in rats with hyperglycemia Фармация и фармакология (Пятигорск) anticoagulant activity blood glucose level complex compound fibrinolysis glyprolin peptides hyperglycemia type 2 diabetes mellitus (t2dm) |
| title | Pharmacology complex compound of pro-gly-pro-leu with heparin: hypoglycemic, fibrinolitic and anticoagulant effects in rats with hyperglycemia |
| title_full | Pharmacology complex compound of pro-gly-pro-leu with heparin: hypoglycemic, fibrinolitic and anticoagulant effects in rats with hyperglycemia |
| title_fullStr | Pharmacology complex compound of pro-gly-pro-leu with heparin: hypoglycemic, fibrinolitic and anticoagulant effects in rats with hyperglycemia |
| title_full_unstemmed | Pharmacology complex compound of pro-gly-pro-leu with heparin: hypoglycemic, fibrinolitic and anticoagulant effects in rats with hyperglycemia |
| title_short | Pharmacology complex compound of pro-gly-pro-leu with heparin: hypoglycemic, fibrinolitic and anticoagulant effects in rats with hyperglycemia |
| title_sort | pharmacology complex compound of pro gly pro leu with heparin hypoglycemic fibrinolitic and anticoagulant effects in rats with hyperglycemia |
| topic | anticoagulant activity blood glucose level complex compound fibrinolysis glyprolin peptides hyperglycemia type 2 diabetes mellitus (t2dm) |
| url | https://www.pharmpharm.ru/jour/article/view/516 |
| work_keys_str_mv | AT tyuobergan pharmacologycomplexcompoundofproglyproleuwithheparinhypoglycemicfibrinoliticandanticoagulanteffectsinratswithhyperglycemia AT nfmyasoedov pharmacologycomplexcompoundofproglyproleuwithheparinhypoglycemicfibrinoliticandanticoagulanteffectsinratswithhyperglycemia AT megrigorjeva pharmacologycomplexcompoundofproglyproleuwithheparinhypoglycemicfibrinoliticandanticoagulanteffectsinratswithhyperglycemia AT lalyapina pharmacologycomplexcompoundofproglyproleuwithheparinhypoglycemicfibrinoliticandanticoagulanteffectsinratswithhyperglycemia AT tashubina pharmacologycomplexcompoundofproglyproleuwithheparinhypoglycemicfibrinoliticandanticoagulanteffectsinratswithhyperglycemia AT laandreeva pharmacologycomplexcompoundofproglyproleuwithheparinhypoglycemicfibrinoliticandanticoagulanteffectsinratswithhyperglycemia |